









市场行情
/
股票
/
nasdaq-fate
/

Fate Therapeutics Inc

FATE

1.140USD

+0.020+1.79%

交易中（美东）报价延迟15分钟

131.48M总市值

亏损市盈率 TTM



Fate Therapeutics Inc

1.140

+0.020+1.79%

概览公司财务分析

概览

公司

财务

分析

关于 Fate Therapeutics Inc 公司

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Fate Therapeutics Inc简介



公司代码FATE

公司名称Fate Therapeutics Inc

上市日期Oct 01, 2013

CEOValamehr (Bahram)

员工数量181

证券类型Ordinary Share

年结日Oct 01

公司地址12278 Scripps Summit Drive

城市SAN DIEGO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编92131

电话18588751803

网址https://fatetherapeutics.com/

公司代码FATE

上市日期Oct 01, 2013

CEOValamehr (Bahram)

Fate Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. William H. (Bill) Rastetter, Ph.D.

Independent Chairman of the Board

617.42K

Mr. Kamal Adawi

Chief Financial Officer

75.00K

Dr. Bahram Valamehr, Ph.D.

President, Chief Executive Officer, Director

65.61K

-18.06%

Ms. Cindy R. Tahl, J.D.

Chief Legal and Compliance Officer, Corporate Secretary

58.39K

-13.40%

Dr. Robert S. (Rob) Epstein, M.D.

Independent Director

11.33K

Dr. Shefali Agarwal, M.D.

Independent Director

10.49K

Dr. Karin Jooss, Ph.D.

Independent Director

9.85K

Dr. Xu Yuan, Ph.D.

Independent Director

Mr. Michael Lee

Independent Director

Mr. Matthew C. Abernethy, CPA

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. William H. (Bill) Rastetter, Ph.D.

Independent Chairman of the Board

617.42K

Mr. Kamal Adawi

Chief Financial Officer

75.00K

Dr. Bahram Valamehr, Ph.D.

President, Chief Executive Officer, Director

65.61K

-18.06%

Ms. Cindy R. Tahl, J.D.

Chief Legal and Compliance Officer, Corporate Secretary

58.39K

-13.40%

Dr. Robert S. (Rob) Epstein, M.D.

Independent Director

11.33K

Dr. Shefali Agarwal, M.D.

Independent Director

10.49K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

Redmile Group, LLC

11.16%

ARK Investment Management LLC

8.94%

The Vanguard Group, Inc.

7.63%

BlackRock Institutional Trust Company, N.A.

7.36%

Wilshire Advisors LLC

7.36%

其他

57.56%

持股股东

占比

Redmile Group, LLC

11.16%

ARK Investment Management LLC

8.94%

The Vanguard Group, Inc.

7.63%

BlackRock Institutional Trust Company, N.A.

7.36%

Wilshire Advisors LLC

7.36%

其他

57.56%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

35.47%

Investment Advisor

29.79%

Hedge Fund

8.07%

Venture Capital

3.31%

Research Firm

2.58%

Individual Investor

1.52%

Pension Fund

0.13%

Family Office

0.12%

Bank and Trust

0.11%

其他

18.91%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

362

90.58M

121.91%

2025Q3

392

90.63M

123.83%

-62.33K

2025Q2

417

90.67M

126.20%

-17.10M

2025Q1

428

107.83M

118.91%

-28.45M

2024Q4

466

102.82M

135.16%

-13.40M

2024Q3

501

116.61M

140.28%

-7.11M

2024Q2

512

123.74M

135.30%

-845.14K

2024Q1

525

124.52M

115.54%

-6.97M

2023Q4

539

96.81M

133.02%

-789.66K

2023Q3

563

97.53M

144.16%

-13.48M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Redmile Group, LLC

12.88M

11.17%

+11.33K

+0.09%

Jul 02, 2025

ARK Investment Management LLC

10.31M

8.94%

+10.31M

Mar 31, 2025

The Vanguard Group, Inc.

8.77M

7.6%

-1.54M

-14.97%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.61M

7.47%

+225.50K

+2.69%

Jun 30, 2025

Johnson & Johnson Innovation-JJDC, Inc.

3.38M

2.93%

Jun 30, 2025

Acadian Asset Management LLC

2.46M

2.13%

-13.61K

-0.55%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.43M

2.11%

+159.56K

+7.03%

Jun 30, 2025

Vestal Point Capital, LP

2.52M

2.18%

-850.00

-0.03%

Jun 30, 2025

State Street Investment Management (US)

2.23M

1.93%

+119.06K

+5.64%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco NASDAQ Future Gen 200 ETF

0.7%

WisdomTree BioRevolution Fund

0.28%

iShares Micro-Cap ETF

0.03%

ProShares Ultra Nasdaq Biotechnology

0.02%

Invesco Nasdaq Biotechnology ETF

0.02%

iShares Russell 2000 Value ETF

0.01%

Global X Russell 2000 ETF

0.01%

Proshares Ultra Russell 2000

0.01%

iShares Biotechnology ETF

0.01%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

Invesco NASDAQ Future Gen 200 ETF

占比0.7%

WisdomTree BioRevolution Fund

占比0.28%

iShares Micro-Cap ETF

占比0.03%

ProShares Ultra Nasdaq Biotechnology

占比0.02%

Invesco Nasdaq Biotechnology ETF

占比0.02%

iShares Russell 2000 Value ETF

占比0.01%

Global X Russell 2000 ETF

占比0.01%

Proshares Ultra Russell 2000

占比0.01%

iShares Biotechnology ETF

占比0.01%

Invesco RAFI US 1500 Small-Mid ETF

占比0.01%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Fate Therapeutics Inc的前五大股东是谁？



Fate Therapeutics Inc 的前五大股东如下：
Redmile Group, LLC持有股份：12.88M，占总股份比例：11.17%。
ARK Investment Management LLC持有股份：10.31M，占总股份比例：8.94%。
The Vanguard Group, Inc.持有股份：8.77M，占总股份比例：7.60%。
BlackRock Institutional Trust Company, N.A.持有股份：8.61M，占总股份比例：7.47%。
Johnson & Johnson Innovation-JJDC, Inc.持有股份：3.38M，占总股份比例：2.93%。